Denbri 60mg Injection contains the active ingredient Denosumab, a medication used to treat osteoporosis, a condition in which bones become weakened. It is also prescribed to help prevent bone complications in patients with certain types of cancer, such as multiple myeloma and bone metastases.

Denbri works by inhibiting a protein called RANK ligand, which is involved in the breakdown of bone tissue. By blocking this protein, Denbri helps to increase bone density and reduce the risk of fractures, especially in postmenopausal women with osteoporosis and cancer patients who experience bone loss due to their condition. Patients with moderate renal impairment may require close monitoring of renal function during treatment.

It is important to ensure adequate calcium and vitamin D intake while using Denbri. The medication should not be used in individuals with known hypersensitivity or allergic reactions to any of its components. Denbri is not approved for use in children and adolescents, as its safety and effectiveness in individuals under 18 have not been established. Caution is also recommended for individuals with pre-existing hypoparathyroidism, a condition characterized by low parathyroid hormone levels.

Patients should consult their healthcare provider to confirm if Denbri is the appropriate treatment for their condition.